HIGHLIGHT
Tagrisso

Tagrisso Indications/Uses

Manufacturer:

AstraZeneca

Distributor:

DKSH
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Indications/Uses
TAGRISSO (osimertinib) is indicated for: the adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations; the first-line treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations; the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in